Nutra Pharma CORP

Nutra Pharma Corp. announced the resignation of Marcum LLP as its independent auditor and the appointment of Astra Audit & Advisory, citing material weaknesses in internal controls.

Nutra Pharma Corp. has announced the resignation of its CEO, Rik J. Deitsch, following a settlement with the SEC, and the appointment of Dr. Michael Flax as the new CEO, Chairman, and CFO.

Nutra Pharma Corp. reports a net loss of $459,675 for Q1 2026, citing ongoing liquidity challenges and significant debt defaults.

Nutra Pharma Corp. reported a wider net loss for the third quarter and first nine months of 2025, driven by increased operating expenses and fluctuations in derivative liabilities, despite a rise in net sales to unrelated customers.

Nutra Pharma Corp. reported a net income of $369,577 for Q2 2025, driven by non-operating gains, despite ongoing substantial doubt about its ability to continue as a going concern due to significant accumulated deficits and debt defaults.

Nutra Pharma Corp. reported a widened net loss for Q2 2024 and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

Nutra Pharma Corp. reported a significant net loss and declining revenues for Q1 2024, raising substantial doubt about its ability to continue as a going concern.

Nutra Pharma Corp. reported a significant net loss for the nine months ended September 30, 2023, alongside substantial debt and ongoing legal challenges, raising going concern doubts.

Nutra Pharma Corp. reports significant net losses and substantial doubt regarding its ability to continue as a going concern in its 2025 annual report.

Nutra Pharma Corp. reported continued net losses and a significant working capital deficit for fiscal year 2024, raising substantial doubt about its ability to continue as a going concern, while also settling a major SEC lawsuit.

Nutra Pharma Corp. reported a net loss of $1.39 million in 2023, a significant decline from the prior year's net income, while settling an SEC lawsuit and undergoing a CEO transition.

Nutra Pharma Corp. reported a net income of $8.18 million for 2022, primarily driven by a non-cash gain from derivative revaluation, while facing a significant SEC settlement and a change in executive leadership.